Daratumumab for the treatment of multiple myeloma.

about

New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.CAR T cell therapy for multiple myeloma: where are we now and where are we headed?Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe.

P2860

Q47221234-8FD48DC7-2205-4B42-8BD6-6F2AEF15CCA9 Q47565827-754CF975-60A8-4A77-B374-7E4B3976F7B3 Q48537667-3E2D9442-38DA-4FB7-9525-091A6CC515DF

P2860

Daratumumab for the treatment of multiple myeloma.

Item

http://www.wikidata.org/entity/Q38824538

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Daratumumab for the treatment of multiple myeloma.

@en

type

Item

label

Daratumumab for the treatment of multiple myeloma.

@en

prefLabel

Daratumumab for the treatment of multiple myeloma.

@en

P1476

Daratumumab for the treatment of multiple myeloma.

@en

P2093

Cyrille Touzeau

http://www.w3.org/2001/XMLSchema#string

Philippe Moreau

http://www.w3.org/2001/XMLSchema#string

P2860

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond

Multiple myeloma: from front-line to relapsed therapies

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

Resolving the daratumumab interference with blood compatibility testing.

P304

887-893

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14712598.2017.1322578

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28434255

http://www.w3.org/2001/XMLSchema#string

Daratumumab for the treatment of multiple myeloma.

about

P2860

P2860

Daratumumab for the treatment of multiple myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698